subject: The Postmodern Life Of Metformin Sizable Domestic Market [print this page] Field of diabetes treatment in recent years have only a few "blockbuster" potential anti-diabetes drug market, but experienced a 50-year career in the classical market of drug metformin, is still under the effective control of human diabetes, the war worked hard
With the people's living standards and lifestyle changes, the "rich man's disease," said the incidence of diabetes shows rapid rise in violent trend. So far, the global type 2 diabetes have 250 million people, is expected to reach 380 million by 2025 people. Posted in ResearchandMarkets "diabetes market outlook 2011" report: 2005 Global Diabetes drug market has reached 186 billion U.S. dollars, an increase of 11.5% the previous year. In 2006, the global diabetes drug market crossed the 200 billion mark.
Considerable domestic market capacity China, as a large population, rapidly rising incidence of diabetes grim situation alarming. According to relevant statistics, China has reached 3,000 people with diabetes, prevalence rate of about 2% to 4%, and to add 1 million patients per year rate of increase, China has become the world's second largest country in diabetes, 2 the great majority of diabetic patients. In the past 20 years, China's incidence of diabetes increased five times. According to estimates, China's diabetes drug market reached 13 billion yuan, and has become the cardiovascular, Cancer Serious harm to people's health after the third largest disease.
More worrying is that many complications of diabetes can occur, and some direct threat to the lives of patients. Research shows that 10 years after onset diabetes, 30% to 40% of patients at least a complication occurs. According to Shanghai Jiaotong University, Ruijin Hospital, Professor Chen Mingdao introduced in 2006 ADA annual meeting, the scientists concluded the clinical complications of type 2 diabetes include: large vascular disease, cerebrovascular disease (incidence rate 10.2%), cardiovascular disease (incidence rate 25.3%), peripheral vascular disease (incidence rate 10.6%); microvascular complications retinopathy (incidence rate 33.1%), renal disease (incidence rate 20.9%), peripheral neuropathy (incidence 41.5%). Type 2 diabetes the risk of cardiovascular disease and stroke than the general population of 2 to 4 times higher, the patient will be reduced by 5 to 10 years of life. In all diabetes-related deaths, 80% of cardiovascular disease (CVD), and therefore, the medical profession has been active in taking all measures to do its utmost to reduce the risk of type 2 diabetes, cardiovascular factors.
Charming lilac
1918, the pharmacists found that guanidine substances in plants can reduce the urine, and targeting the goat beans (French lilac, Galegaofficinalis, goat'srue) on; in 1922, scientists will be lilac in Ireland components with hypoglycemic effect of metformin for the first time the successful synthesis; in 1957, from Bristol-Myers Squibb (BMS) patent metformin has been approved in France for the first time used as a clinical hypoglycemic drugs, and the name "Glucophage ( Glucophage) ". In the following 50 years, as the first one oral hypoglycemic drug metformin, has become the classic type 2 diabetes medication, and in December 29, 1994 the U.S. FDA approval to market. In 1998, UKPDS landmark study (United Kingdom Prospective Diabetes Study) confirmed the long-term benefits of metformin on cardiovascular protection; in 2002, the EU approved Glucophage for 10 to 16 year-old children with type 2 diabetes. Company BMS ( ) original patent shall expire that year on March 3, 2005 is based on the age of 10 to 16 pediatric patients with type 2 diabetes, clinical studies, FDA will Glucophage ( ) extension of the patent 6 months, this decision is a supplementary new drug application for the drug (SNDA), which was being reviewed. In 2007, China's diabetes, metformin has become the new guidelines the only choice for obese patients with oral hypoglycemic drugs.
The Postmodern Life Of Metformin Sizable Domestic Market
